Virus Filters Markets Poised for Strong Growth Through 2035 on Biologics Demand
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
The global markets for virus filters used in biopharmaceutical manufacturing are projected for significant growth through 2035, driven by expanding production of biologics and increasingly stringent viral safety regulations. A new market outlook indicates that demand is accelerating as regulatory mandates make viral filtration a non-negotiable step in the manufacturing of monoclonal antibodies, gene therapies, and other advanced medicinal products.
The global virus filters market is projected to grow at a compound annual growth rate (CAGR) of approximately 8.2% from 2026 to 2035, with a market index forecast to reach 220 by 2035 (2025=100). For the specific biotherapeutics virus removal filters segment, the baseline scenario projects a CAGR of approximately 7.2% over the same period, with the market index reaching 195 by 2035 relative to a 2025 baseline of 100. This growth is structurally anchored in the expansion of biopharmaceutical manufacturing capacity, particularly for monoclonal antibodies (mAbs) and advanced therapy medicinal products (ATMPs) like gene therapies and CAR-T cell therapies.
Regulatory frameworks, such as ICH Q5A (R1), are tightening viral safety requirements, mandating dedicated virus filtration steps for a broader range of products including biosimilars. This creates a non-discretionary, high-stakes purchasing environment. The market is characterized by high switching costs due to validation burdens, which favor incumbent suppliers. Pricing is multi-layered, with filter unit cost being only part of the total cost of ownership, which includes validation services, technical support, and long-term supply agreements.
The rise of contract development and manufacturing organizations (CDMOs) is acting as a powerful demand aggregator, shifting buyer influence. The adoption of single-use technologies in bioprocessing is further driving demand for disposable virus removal filter assemblies, which reduce cross-contamination risk and improve operational flexibility. Geographic demand is diversifying, with established regions like the U.S., Western Europe, and Japan leading innovation, while Asia-Pacific drives commercial-scale volume growth. New biomanufacturing hubs in China, South Korea, and Singapore are scaling up, and the region is expected to gain market share.
Monoclonal antibody production remains the largest end-use segment, accounting for approximately 38% of market demand for biotherapeutics virus removal filters. This segment requires high-throughput, standardized filtration steps for retrovirus and parvovirus clearance. The trend toward intensified and continuous bioprocessing is pushing suppliers to develop higher-capacity, single-use devices. ATMPs represent the fastest-growing end-use segment, driven by the surge in gene therapy and CAR-T cell therapy approvals.
The market supply is concentrated among a few global players with proprietary membrane casting expertise and comprehensive regulatory support packages, raising barriers to entry. Representative participants include Merck KGaA (MilliporeSigma), Danaher Corporation (Pall Corporation), Sartorius AG, Cytiva (Danaher), and Repligen Corporation. Increasing competition is also emerging from regional manufacturers in China and India developing cost-competitive filters.